{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:17:33Z","timestamp":1780471053179,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cllc.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T02:41:13Z","timestamp":1658371273000},"page":"571-577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"23","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Londhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthiv","family":"Mahadevia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.07.007_bib0001","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.007_bib0002","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2022.07.007_bib0003","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cllc.2022.07.007_bib0004","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.007_bib0005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2022.07.007_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.007_bib0007","doi-asserted-by":"crossref","first-page":"102105","DOI":"10.1016\/j.ctrv.2020.102105","article-title":"EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins","volume":"90","author":"Remon","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cllc.2022.07.007_bib0008","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdz141","article-title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","volume":"30","author":"Hastings","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.07.007_bib0009","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.007_bib0010","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.007_bib0011","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2022.07.007_bib0012","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A Phase II study of pembrolizumab in EGFR-Mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.007_bib0013","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/1759-7714.13748","article-title":"Immune microenvironment features and efficacy of PD-1\/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions","volume":"12","author":"Chen","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2022.07.007_bib0014","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cllc.2020.12.015","article-title":"Subtypes of EGFR- and HER2-mutant metastatic NSCLC influence response to immune checkpoint inhibitors","volume":"22","author":"Lau","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2022.07.007_bib0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/genes12050679","article-title":"Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations","volume":"12","author":"Metro","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.cllc.2022.07.007_bib0016","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-20-4650","article-title":"Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions","volume":"27","author":"Choudhury","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.07.007_bib0017","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.007_bib0018","doi-asserted-by":"crossref","first-page":"732214","DOI":"10.3389\/fonc.2021.732214","article-title":"The predictive value of clinical and molecular characteristics or immunotherapy in non-small cell lung cancer: a meta-analysis of randomized controlled trials","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2022.07.007_bib0019","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:13:13Z","timestamp":1761505993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422001589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1525730422001589"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}